ARN-509
ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16nM, useful for prostate cancer treatment. Phase 3
ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16nM, useful for prostate cancer treatment. Phase 3
